

Mometasone Suspension Formulation

Version 3.3 Revision Date: 05/02/2017 SDS Number: 23614-00008 Date of last issue: 01/10/2017
Date of first issue: 10/21/2014

SECTION 1. IDENTIFICATION

Product name : Mometasone Suspension Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Glycerine	56-81-5	≥ 1 - < 5
Mometasone	83919-23-7	< 0.1

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages

Mometasone Suspension Formulation

Version 3.3 Revision Date: 05/02/2017 SDS Number: 23614-00008 Date of last issue: 01/10/2017
 Date of first issue: 10/21/2014

cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
 For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
 Clean up remaining materials from spill with suitable absorbent.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice.
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	TWA (mist, respirable fraction)	5 mg/m ³	OSHA Z-1
		TWA (mist, total dust)	15 mg/m ³	OSHA Z-1
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Merck
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Merck

Engineering measures : Ensure adequate ventilation, especially in confined areas.
 Minimize workplace exposure concentrations.
 Dust formation may be relevant in the processing of this

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Remarks : Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety glasses

Skin and body protection : Skin should be washed after contact.

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Color	: White to light yellow
Odor	: odorless
Odor Threshold	: No data available
pH	: 4.3 - 4.9
Melting point/freezing point	: No data available
Initial boiling point and boiling	: No data available

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

range

Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	1 g/cm ³
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:**Glycerine:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Glycerine:**

Result: No skin irritation

Mometasone:

Species: Rabbit
Result: No skin irritation

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Glycerine:**

Result: No eye irritation

Mometasone:

Species: Rabbit

Result: No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Mometasone:**

Test Type: Maximization Test

Routes of exposure: Dermal

Species: Guinea pig

Assessment: Does not cause skin sensitization.

Result: negative

Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**Glycerine:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

: Test Type: Chromosomal aberration
Species: Chinese hamster lung cells
Result: negative

: Test Type: Chromosomal aberration
Species: Chinese hamster ovary cells
Result: positive

: Test Type: Mouse Lymphoma

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Ingredients:**Glycerine:**

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Mometasone:

Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Reproductive toxicity

Not classified based on available information.

Ingredients:**Glycerine:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rabbit Application Route: Ingestion Result: negative

Mometasone:

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Result: No effects on fertility.
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Mouse Application Route: Subcutaneous Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmental toxicity Test Type: Embryo-fetal development Species: Rat Application Route: Dermal Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight Result: Embryo-fetal toxicity. Test Type: Embryo-fetal development Species: Rabbit Application Route: Dermal Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight Result: Embryo-fetal toxicity., Malformations were observed. Test Type: Embryo-fetal development Species: Rat Application Route: Subcutaneous Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight Result: Effects on newborn. Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight Result: Embryo-fetal toxicity., Malformations were observed.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Ingredients:**Mometasone:**

Remarks: Based on available data, the classification criteria are not met.

STOT-repeated exposure

Not classified based on available information.

Ingredients:**Mometasone:**

Routes of exposure: inhalation (dust/mist/fume)

Target Organs: Immune system, Liver, Kidney, Skin

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Ingredients:****Glycerine:**

Species: Rat

NOAEL: 167 mg/m³

LOAEL: 660 mg/m³

Application Route: inhalation (dust/mist/fume)

Exposure time: 13 Weeks

Symptoms: Local irritation

Mometasone:

Species: Rat

NOAEL: 0.005 mg/kg

LOAEL: 0.3 mg/kg

Application Route: Oral

Exposure time: 30 d

Target Organs: lymph node, Liver, Adrenal gland, Skin, thymus

Species: Dog

LOAEL: 0.5 mg/kg

Application Route: Oral

Exposure time: 30 d

Target Organs: lymph node, Liver, Adrenal gland, Skin, thymus

Species: Rat

NOAEL: 0.00013 mg/l

Application Route: inhalation (dust/mist/fume)

Exposure time: 90 d

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Target Organs: Adrenal gland, Lungs, lymph node, spleen, Bone marrow, Kidney, Liver, thymus

Species: Dog

NOAEL: 0.0005 mg/l

Application Route: inhalation (dust/mist/fume)

Exposure time: 90 d

Target Organs: Adrenal gland, Lungs, lymph node, spleen, Bone marrow, Kidney, thymus, Liver

Aspiration toxicity

Not classified based on available information.

Ingredients:**Mometasone:**

No aspiration toxicity classification

Experience with human exposure**Ingredients:****Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Ingredients:****Mometasone:**

Remarks: Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
aquatic invertebrates Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

- Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
- EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.
- Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.
- M-Factor (Chronic aquatic toxicity) : 100
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.
- NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Persistence and degradability**Ingredients:****Glycerine:**

- Biodegradability : Result: Readily biodegradable.
Biodegradation: 94 %

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Exposure time: 1 d

Mometasone:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential**Ingredients:****Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.76

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Mometasone, Benzalkonium chloride)

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3082
 Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
 (Mometasone, Benzalkonium chloride)

Class : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 964
 Packing instruction (passenger aircraft) : 964

IMDG-Code

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
 N.O.S.
 (Mometasone, Benzalkonium chloride)

Class : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3082
 Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
 (Mometasone, Benzalkonium chloride)
 Class : 9
 Packing group : III
 Labels : CLASS 9
 ERG Code : 171
 Marine pollutant : yes(Mometasone, Benzalkonium chloride)
 Remarks : Above applies only to containers over 119 gallons or 450
 liters., Shipment by ground under DOT is non-regulated;
 however it may be shipped per the applicable hazard
 classification to facilitate multi-modal transport involving ICAO
 (IATA) or IMO.

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

Mometasone Suspension Formulation

Version 3.3 Revision Date: 05/02/2017 SDS Number: 23614-00008 Date of last issue: 01/10/2017
 Date of first issue: 10/21/2014

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Water 7732-18-5
 Glycerine 56-81-5

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

California Permissible Exposure Limits for Chemical Contaminants

Glycerine 56-81-5


The ingredients of this product are reported in the following inventories:

AICS : not determined
 DSL : not determined
 IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

OSHA Z-1 / TWA : its for Air Contaminants
: 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/02/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 01/10/2017
3.3	05/02/2017	23614-00008	Date of first issue: 10/21/2014

US / Z8